Drug Profile

PMS 201

Alternative Names: PMS-201

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Feb 2025 Early research in Pneumonia in South Korea (Parenteral) prior to February 2025 (Primoris Therapeutics pipeline, February 2025)
10 Jun 2024 Primoris Therapeutics files for patent protection for 'Manufacturing method and usage of conditioned media which contains highly effective exosomes secreted by umbilical cord blood stem cells at high content' in South Korea
04 Jan 2024 Primoris Therapeutics has patents pending entitled "Method for preparing high-concentration stem cell exosomes with enhanced anti-inflammatory and regenerative functions using lipopolysaccharide and lipoteichoic acid" in the US

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com